Lowe’s stock closes lower as Wall Street slips; housing data and Fed minutes in focus

Lowe’s stock closes lower as Wall Street slips; housing data and Fed minutes in focus

NEW YORK, December 29, 2025, 10:26 PM ET — Market closed.

  • Lowe’s (LOW) ended down 0.14% at $243.48; it last traded at $243.83 after-hours.
  • U.S. pending home sales jumped to the highest level since February 2023.
  • Traders are lining up Fed minutes and home-price data ahead of Tuesday’s session.

Lowe’s Companies Inc shares finished Monday down 0.14% at $243.48. The stock was last indicated at $243.83 in after-hours trading.

The move kept Lowe’s near a level investors have treated as a referendum on the U.S. housing cycle and interest-rate direction. Home-improvement spending can firm when mortgage rates ease and housing turnover rises, but it tends to stall when homeowners delay big projects.

Housing data delivered a fresh data point late in the session. Contracts to buy existing homes — known as pending home sales, a gauge of signed deals that typically turn into closings a month or two later — rose 3.3% in November, the National Association of Realtors said. “Homebuyer momentum is building,” chief economist Lawrence Yun said. Reuters

The broader tape offered little help. The S&P 500 fell 0.35%, the Nasdaq dropped 0.50% and the Dow lost 0.51% as heavyweight technology shares retreated from last week’s gains, Reuters reported.

Home-improvement retailers moved largely in step with the market’s drift. Home Depot, Lowe’s closest peer, fell 0.67% on the day.

Lowe’s last reshaped investor expectations in November, when it trimmed annual profit and sales forecasts as shoppers deferred bigger renovation work. The retailer pointed to its push to win more professional contractor business as it navigated uneven do-it-yourself demand.

Before Tuesday’s session, traders will focus on the Federal Reserve’s December meeting minutes for signals on how policymakers see the 2026 rate path. Trading has been thin into year-end, which can exaggerate moves, Reuters reported.

Housing-linked releases are also on deck. The S&P CoreLogic Case‑Shiller home price index for October is scheduled for 9 a.m. ET on Tuesday, based on CME Group’s Econoday calendar.

The next company-specific marker is Lowe’s fourth-quarter earnings conference call, listed on its investor calendar as an estimated Feb. 25 event. Investors will watch comparable sales — sales at stores open at least a year — along with updates on Pro demand and margins.

On the chart, traders have treated the $240 area as a key pivot. MarketBeat data put Lowe’s 50-day moving average at $239.87 and its 200-day at $240.62, with a 12-month range of $206.38 to $274.98.

A clearer pickup in housing turnover and affordability would typically support renovation spending, but investors will be watching whether that momentum shows up in traffic and larger project tickets. Until then, Lowe’s trading is likely to stay tethered to rates, housing data and shifting year-end positioning.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Danaher stock beats Wall Street dip as investors eye Fed minutes and Jan. 28 earnings
Previous Story

Danaher stock beats Wall Street dip as investors eye Fed minutes and Jan. 28 earnings

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms
Next Story

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms